CEFOXITIN
Klatskin Tumor
Yonsei UniversitySmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Klatskin Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Capecitabine National Cancer Institute (NCI) | Phase 2 | B |
FLUOROURACILUM National Cancer Institute (NCI) | Phase 2 | B |
gsk1120212 National Cancer Institute (NCI) | Phase 2 | B |
ADH-1 TRIFLUROACETATE University of Nebraska | Phase 1 | CC |
CIS-DIAMMINEDICHLOROPLATINUM II University of Nebraska | Phase 1 | CC |
Same molecule, other indications
CEFOXITIN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →